Atlas Trials

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Clinical trial NCT04129710 · UNKNOWN

Trial details

NCT number
NCT04129710
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
Start date
2020-01-01
Primary completion
2023-12-31
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.